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1. Introduction 
Interferons are known to affect mononuclear phag- 
ocyte functions both in vitro and in vivo. Enhanced 
spreading on growth substratum [ 1,2] as well as 
increased phagocytic [3] and tumoricidal [ 1,4] activ- 
ities have been described in cultured macrophages 
after exposure to interferons [IFN). Increased phag- 
ocytic activity of macrophages is likewise evident in 
vivo in animals treated with interferon [5,6]. Human 
monocytes exposed in vitro to interferon have also 
been reported to show enhanced phagocytic activity 
[7] as well as increased capacity to kill tumour [B] 
and virus-infected cells [9]. However, in [lo] both 
leukocyte and fibroblast interferon reversibly inhibited 
morphological differentiation of human monocytes 
to macrophages in culture; this phenomenon might 
have had a role in IFN-induced immunosuppression 
[lOI- 
We have also found that interferons can inhibit 
monocyte-macrophage transition in culture as judged 
by morphology, but we show here that thii does not 
necessarily result in an inhibition of the development 
of cellular functions such as secretion of plasminogen 
activator. Moreover, low concentrations of interferon 
Q were found to effectively enhance the secretion of 
this specific protease by human blood monocyte- 
derived macrophages. 
2. Materials and methods 
2.1. Monocy te cultures 
Mononuclear leukocytes were isolated by standard 
techniques [ 111 from the buffy coat fraction of human 
blood provided by the Finnish Red Cross Blood Trans- 
fusion Centre (Helsinki). 
ElsevierlNorth-Holland Biomedical Press 
Monocytes were purified by a double-adherence 
method (0. S., T. H., A. V., submitted) and cultured 
in a 1: 1 mixture of medium 199 and RPM1 1640 
(obtained in powder form from Flow Labs., Glasgow) 
supplemented with lO%newborn calf serum [12,13]. 
More than 95% of the adherent cells in these cultures 
showed the monocyte marker nonspecific esterase as 
assayed according to [ 141. 
2.2. In terferons and interferon antisera 
All interferon preparations and antisera were kindly 
put at our disposal by Dr K. Cantell, Helsinki. Stock 
solutions of partially purified human leukocyte inter- 
feron [15], containing 6 X lo6 IU/mg protein, were 
made in Hank’s buffered salt solution, usually at 
50 000 IU/ml, Millipore@-filtered and stored in small 
aliquots at -2O’C. Mock-interferon preparations were 
adjusted to the same protein concentrations. Recom- 
binant DNA-coded Escherichia coli interferon (Hu- 
IFNal (Eco) [ 161 a gift from Dr C. Weissman, Ziirich) 
had spec. act. 4000 IU/ml of protein. Antisera to 
leukocyte interferon used in these experiments had. 
been produced in rabbit or sheep [ 171 and had anti-a- 
interferon titres of 1:75 000 and I:450 000, respec- 
tively . 
2.3. Gzseinolysis-in-gel assay for plasminogen activator 
The method used is detaiIed in [18], and allows 
measuring of plasminogen activator activity in serum- 
containing as well as in serum-free medium samples. 
Plasminogendependence of the observed caseinolysis 
was controlled for each sample. 
2.4. Protein determination 
The Lowry method [ 191 was applied using bovine 
serum albumin as standard. 
233 
Volume 129, number 2 FEBS LETTERS July 1981 
= 0.06- 
* 
E 
f 
5 0.04. 
I 
a02 - 
O- 
I23456 I23456 
A B 
3. Results 
We have found that secretion of plasminogen acti- 
vator, a specific serine protease [20], by human mono- 
cyte-macrophages shows a temporal concurrence with 
the morphological transition (0. S., T. H., A. V., sub- 
mitted). Supematants of fresh monocyte cultures were 
devoid of this enzyme activity while those of differen- 
tiated cell cultures showed increasing levels of activity 
measurable by the sodium dodecyl sulfate (SDS)- 
enhanced caseinolysis-in-gel method (fig.1). In con- 
trast, cell-associated plasminogen activator activity was 
already readily demonstrable in fresh monocyte cul- 
tures without SDS treatment, as in [21-231. A detailed 
23466 
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Fig.1. Effect of interferon on plasminogen activator secretion 
by human monocyte-macrophage cultures. Culture media of 
24 h monocytes were supplemented with various concentra- 
tions of interferon (dotted columns l-6), mock-interferon 
(white columns 3-6) or left without additions (white l-2). 
Interferonconcentrations (W/ml) were: 1.7 (1),5 (2), 17 (3), 
50 (4), 167 (5) and 500 (6). Mock-treated cultures received 
respective amounts of mock-protein. Supernatants were har- 
vested every second day (A, O-2 days; B, 2-4 days; C, 4-6 
days), cleared from detached cells by a brief centiifugation 
and assayed for plasminogen activator activity. Medium 
replacements were carried out without readding interferon; 
pu, ploug units [24]. 
description of the kinetics of plasminogen activator 
release from monocyte-macrophages is described else- 
where (0. S., T. H., A. V., submitted). 
Secretion of plasminogen activator by monocyte- 
macrophages was greatly enhanced when 24 h mono- 
cyte cultures were exposed to low concentrations of 
human leukocyte interferon. Higher doses of inter- 
feron caused less stimulation of the enzyme secretion 
(fig.1). Mock-interferon preparations had no effects 
on plasminogen activator activities (fig.1) while two 
different antisera against human leukocyte interferon 
inhibited the stimulation of plasminogen activator 
secretion (not shown). When the cultures were exposed 
to interferon at a stage when definite morphological 
0 
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Fig.2. Effect of interferon on plasminogen activator secretion 
by differentiated macrophages. Cultures were prepared as for 
fig.1, but interferon was added only after 4 days’ incubation 
when most of the cells already showed morphological signs of 
differentiation. For symbols see legend for fig.1. The inter- 
feron-induced increase in plasminogen activator activity in 
the medium was maximally -2O-fold, but when calculated 
per protein in the cell layer, the increase was even greater, 
maximally 30-40-fold. The final cellular protein masses in 
the experiment were 100 (l), 105 (2), 100 (3), 80 (4), 65 (5) 
and 42 Mg/culture (6) in the interferon-treated cultures, and 
between 100 and 120 &culture in all control and mock- 
treated cultures. 
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Table 1 
Effect of recombinant DNA-coded interferon on plasminogen 
activator production by human macrophages 
Culture Plasminogen activator activity 
in culture medium (PU/ml) 
4 days 6 days 
Control 0.01 0.08 
+ IFN+, @co) 5 III/ml 0.01 0.10 
+ IFN+, (Eco) 17 W/ml 0.01 1.10 
+ IFN_(y, (x%x) 50 IU/ml 0.03 1.50 
+ IFNx-@e) 5 IU/ml 0.01 0.20 
+ IFNa(Le) 17 III/ml 0.02 1.00 
+ IFNaY 50 III/ml 0.04 1.70 
Recombinant DNA interferon a, produced in E. co/i (IFN*,- 
@co)) and leukocyte interferon (IFNa(Le)) were added to 
oneday monocyte cultures at indicated doses and aliquots of 
culture media were assayed for plasminogen activator activity 
after 4 and 6 days’ incubation 
differentiation was already visible a dose-dependent 
enhancement of the secretion of plasminogen activator 
was seen. Even the highest concentration of interferon 
used (500 III/ml) was still stimulatory in this type of 
experiments (fig.2). This enhancement was not due to 
a general increase in the rate of protein synthesis since 
interferon inhibited the accumulation of cellular pro- 
tein mass (Bg.2). 
As reported in [lo] interferon doses >15-50 IU/ 
ml, when applied on fresh monocytes, reversibly inhib- 
ited the morphological differentiation with most of 
the cells remaining roundish. This inhibition of dif- 
ferentiation was prevented if the interferon prepara- 
tions were preincubated with antisera to leukocyte 
interferon (0. S., T. H., A. V., submitted). 
Both the enhancement of plasminogen activator 
secretion and the inhibition of morphological differen- 
tiation were readily reproducible but the degree of 
both phenomena varied between different batches of 
monocyte cultures. Inhibition of differentiation was 
always more or less directly proportional to the applied 
interferon dose while the maximal enhancement of 
plasminogen activator secretion was obtained within a 
dose range of 1 O-l 80 IU/ml and ranged from 10-40- 
fold. 
The ‘PIF’-grade interferon preparations [ 151 used 
in the above experiments are only -1% pure (K. 
Cantell, personal communication). The antibodies 
raised against them, in spite of producing a high titre 
anti-interferon activity, probably also react against a 
variety of other leukocytederived components in the 
preparations. Thus it is necessary to repeat these 
experiments with highly purified interferon or with 
interferon preparations free of leukocytederived con- 
taminants. We have so far tested one of the various 
recombinant DNA-coded leukocyte interferons pro- 
duced by E. coli [ 161. The effects of this preparation 
on cellular morphology in monocyte-macrophage 
transition (not shown) as well as on plasminogen 
activator secretion were similar to those of the PIF- 
grade leukocyte interferon (table 1). 
4. Discussion 
Our results indicate that human interferon at low 
concentrations can specifically enhance the secretion 
of plasminogen activator, a specific serine protease, 
by human monocyte-derived macrophages in culture. 
This is the first time that a specific proteolytic enzyme 
is shown to be involved in the chain of biochemical 
events following the action of interferon on animal 
cells. That the enhanced enzyme activity indeed was 
due to the action of interferon on the cells and not 
caused by a contaminating leukocyte-derived sub- 
stance in the partially purified interferon prepara- 
tions was suggested by the lack of respective activity 
in adequately prepared mock-interferon, and was fur- 
ther documented by showing a similar dose-dependent 
effect by a recombinant DNA-coded interferon prep- 
aration which most probably has only interferon in 
common with the PIF-interferon. It will be of interest 
to see if the increased secretion of plasminogen acti- 
vator can be correlated to increased motility or to 
alterations in the host-defense functions of these cells. 
Macrophages generally have a greater phagocytic 
activity than monocytes and thus our observation that 
interferons at moderate concentrations appear to 
inhibit monocyte-macrophage transition might be 
considered controversial with the earlier reports that 
interferons enhance phagocytosis both in vitro and in 
vivo [3,5,6]. However, it is important to note that 
concentrations of IFN up to 500 IU/ml, which inhib- 
ited morphological differentiation, did not prevent 
the concomitant induction of plasminogen activator 
secretion but rather potentiated it. This observation 
indicates that development of biochemical charac- 
teristics of monocyte-macrophages in culture can be 
235 
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dissociated from morphological differentiation and 
reinforces the requirement of exact parameter defini- 
tions in describing mononuclear phagocytes at different 
stages of maturation and activation. 
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